BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 23054560)

  • 1. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
    Milde T; Lodrini M; Savelyeva L; Korshunov A; Kool M; Brueckner LM; Antunes AS; Oehme I; Pekrun A; Pfister SM; Kulozik AE; Witt O; Deubzer HE
    J Neurooncol; 2012 Dec; 110(3):335-48. PubMed ID: 23054560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluation.
    Sandén E; Dyberg C; Krona C; Gallo-Oller G; Olsen TK; Enríquez Pérez J; Wickström M; Estekizadeh A; Kool M; Visse E; Ekström TJ; Siesjö P; Johnsen JI; Darabi A
    Sci Rep; 2017 Apr; 7():46366. PubMed ID: 28417956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features.
    Leonard JR; Cai DX; Rivet DJ; Kaufman BA; Park TS; Levy BK; Perry A
    J Neurosurg; 2001 Jul; 95(1):82-8. PubMed ID: 11453402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch1-induced brain tumor models the sonic hedgehog subgroup of human medulloblastoma.
    Natarajan S; Li Y; Miller EE; Shih DJ; Taylor MD; Stearns TM; Bronson RT; Ackerman SL; Yoon JK; Yun K
    Cancer Res; 2013 Sep; 73(17):5381-90. PubMed ID: 23852537
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
    Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor.
    Wang S; Zhang D; Wang J; Peng X; Sun H; Ji Y; Yang Z; Bian X; Hou Y; Ge M; Liu Y
    J Neurooncol; 2024 May; 168(1):139-149. PubMed ID: 38662151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
    Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
    Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts.
    Shu Q; Antalffy B; Su JM; Adesina A; Ou CN; Pietsch T; Blaney SM; Lau CC; Li XN
    Clin Cancer Res; 2006 Aug; 12(15):4687-94. PubMed ID: 16899619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem.
    Grammel D; Warmuth-Metz M; von Bueren AO; Kool M; Pietsch T; Kretzschmar HA; Rowitch DH; Rutkowski S; Pfister SM; Schüller U
    Acta Neuropathol; 2012 Apr; 123(4):601-14. PubMed ID: 22349907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mouse model of the most aggressive subgroup of human medulloblastoma.
    Kawauchi D; Robinson G; Uziel T; Gibson P; Rehg J; Gao C; Finkelstein D; Qu C; Pounds S; Ellison DW; Gilbertson RJ; Roussel MF
    Cancer Cell; 2012 Feb; 21(2):168-80. PubMed ID: 22340591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization.
    Tong CY; Hui AB; Yin XL; Pang JC; Zhu XL; Poon WS; Ng HK
    J Neurosurg; 2004 Feb; 100(2 Suppl Pediatrics):187-93. PubMed ID: 14758948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma.
    Weeraratne SD; Amani V; Neiss A; Teider N; Scott DK; Pomeroy SL; Cho YJ
    Neuro Oncol; 2011 Feb; 13(2):165-75. PubMed ID: 21177782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma.
    Zhao X; Liu Z; Yu L; Zhang Y; Baxter P; Voicu H; Gurusiddappa S; Luan J; Su JM; Leung HC; Li XN
    Neuro Oncol; 2012 May; 14(5):574-83. PubMed ID: 22459127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.
    Vollmer J; Ecker J; Hielscher T; Valinciute G; Ridinger J; Jamaladdin N; Peterziel H; van Tilburg CM; Oehme I; Witt O; Milde T
    J Neurooncol; 2023 Sep; 164(3):617-632. PubMed ID: 37783879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation Sensitivity in a Preclinical Mouse Model of Medulloblastoma Relies on the Function of the Intrinsic Apoptotic Pathway.
    Crowther AJ; Ocasio JK; Fang F; Meidinger J; Wu J; Deal AM; Chang SX; Yuan H; Schmid R; Davis I; Gershon TR
    Cancer Res; 2016 Jun; 76(11):3211-23. PubMed ID: 27197166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. REST is a novel prognostic factor and therapeutic target for medulloblastoma.
    Taylor P; Fangusaro J; Rajaram V; Goldman S; Helenowski IB; MacDonald T; Hasselblatt M; Riedemann L; Laureano A; Cooper L; Gopalakrishnan V
    Mol Cancer Ther; 2012 Aug; 11(8):1713-1723. PubMed ID: 22848092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
    Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
    Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
    Thompson MC; Fuller C; Hogg TL; Dalton J; Finkelstein D; Lau CC; Chintagumpala M; Adesina A; Ashley DM; Kellie SJ; Taylor MD; Curran T; Gajjar A; Gilbertson RJ
    J Clin Oncol; 2006 Apr; 24(12):1924-31. PubMed ID: 16567768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
    Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
    J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic evaluation of isochromosome 17q in posterior fossa tumors of children and correlation with clinical outcome in medulloblastoma. Detection of a novel chromosomal abnormality.
    DeChiara C; Borghese A; Fiorillo A; Genesio R; Conti A; D'Amore R; Pettinato G; Varone A; Maggi G
    Childs Nerv Syst; 2002 Aug; 18(8):380-4. PubMed ID: 12192498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.